查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1783538

肽類 CXO 市場報告：2031 年趨勢、預測與競爭分析

Peptide CXO Market Report: Trends, Forecast and Competitive Analysis to 2031
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

全球胜肽CXO市場前景光明，為製藥公司、生技公司和研究機構帶來機會。預計2025年至2031年期間，全球胜肽CXO市場的複合年成長率將達到10.6%。該市場的主要驅動力包括對個人化醫療日益成長的需求、慢性病盛行率的上升以及對標靶治療的日益關注。

  • Lucintel 預測 CMO/CDMO 將在預測期內經歷最高成長。
  • 從應用角度來看，生物技術公司和研究機構預計將實現高速成長。
  • 按地區分類，預計亞太地區將在預測期內實現最高成長。

這份超過 150 頁的綜合報告提供了寶貴的見解，可協助您做出明智的商業決策。下方展示了部分見解的範例圖表。

胜肽CXO市場的新趨勢

胜肽 CXO 市場受到各種突出趨勢的影響，這些趨勢滿足了生物製藥行業不斷變化的需求以及胜肽合成和製造技術的創新。

  • 複雜修飾胜肽的需求日益成長：更複雜的胜肽（包括長肽、環肽以及聚乙二醇化、脂化和糖基化等化學修飾）的需求日益成長。這些修飾可提高胜肽的穩定性、生物利用度和標靶特異性，從而催生了對具有先進合成和修飾能力的CXO的需求。
  • 自動化和高通量合成技術的應用日益廣泛：為了滿足日益成長的需求並縮短合成時間，自動化和高通量胜肽合成平台的應用日益廣泛。這些技術能夠實現多種胜肽的平行合成，加速藥物發現和研究方法，同時提高效率並降低成本。
  • 綠色和永續肽合成：全球對永續性的日益關注正在推動向更綠色、更永續肽合成過程的轉變，包括使用替代溶劑、減少廢棄物以及更高效的合成和淨化策略，從而減少胜肽生產對環境的影響。
  • 實施先進的分析方法：對純胜肽的需求需要結合先進的分析方法，以實現完整的表徵和品質保證。這些方法包括高效液相層析(HPLC)、質譜法 (MS) 和核磁共振 (NMR) 光譜法，用於檢驗胜肽的純度、特性和結構完整性。
  • GMP級胜肽生產規模擴大：隨著胜肽療法臨床試驗和商業化的推進，GMP級胜肽生產能力正在顯著提升。 CXO正在建立基礎設施和生產能力，以供應符合嚴格品管標準的胜肽，用於人體臨床試驗和商業藥品。

這些新興趨勢正在透過推動合成技術創新、擴大可生產的胜肽範圍、強調永續性、改善品管和提高 GMP 製造能力累積肽 CXO 市場，支持不斷擴大的胜肽療法範圍。

胜肽CXO市場的最新趨勢

胜肽 CXO 市場的最新發展反映了合成、改性和製造技術的持續進步，以及對品質和法規遵循的日益關注。

  • 新型固相合成樹脂和接頭的進展：固相合成的進展包括設計新的樹脂和接頭，以提高胜肽的產量和純度並簡化困難胜肽序列的合成。
  • 連續流肽合成的發展：連續流合成被提倡為胜肽合成的改良放大工藝，提供更高的效率、反應控制、純度和成本效益。
  • 推動酶促肽合成的能力：酶促肽合成由於其高選擇性和在使用侵入性化學品方面的潛在較低成本，正在成為一種更環保的單一胜肽序列方法。
  • 將人工智慧融入胜肽設計和最佳化：人工智慧和基於機器學習的演算法擴大被用於預測胜肽行為、簡化合成通訊協定以及設計具有目標特性的新胜肽序列。
  • 強調品質系統和法規遵循：胜肽 CXO 更重視遵守 GMP 等高度嚴格的監管要求，並建立有效的品管系統，以確保用於研究和治療用途的合成胜肽的安全性和有效性。

這些重要的進步正在徹底改變胜肽 CXO 市場，透過更有效率、更高純度地合成更複雜的胜肽，鼓勵永續的製程實踐，利用胜肽設計中的計算技術，並遵守嚴格的專用品質標準。

目錄

第1章執行摘要

第2章全球胜肽 CXO 市場：市場動態

  • 簡介、背景和分類
  • 供應鏈
  • PESTLE分析
  • 專利分析
  • 法規環境
  • 產業驅動力與挑戰

第3章 2019年至2031年市場趨勢及預測分析

  • 宏觀經濟趨勢（2019-2024）及預測（2025-2031）
  • 全球胜肽 CXO 市場趨勢（2019-2024 年）及預測（2025-2031 年）
  • 全球胜肽 CXO 市場（按類型）
    • CRO：趨勢與預測（2019-2031）
    • CMO/CDMO：趨勢與預測（2019-2031）
  • 全球胜肽 CXO 市場（按應用）
    • 製藥公司：趨勢與預測（2019-2031）
    • 生技公司與研究：趨勢與預測（2019-2031）
    • 其他：趨勢與預測（2019-2031）

第4章2019年至2031年區域市場趨勢與預測分析

  • 全球胜肽 CXO 市場（按地區）
  • 北美胜肽CXO市場
  • 歐洲胜肽CXO市場
  • 亞太胜肽CXO市場
  • 世界其他地區胜肽CXO市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析
    • 競爭對手之間的競爭
    • 買方的議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 新進入者的威脅

第6章 成長機會與策略分析

  • 成長機會分析
    • 全球胜肽 CXO 市場的成長機會（按類型）
    • 全球胜肽 CXO 市場的成長機會（按應用）
    • 全球胜肽 CXO 市場各區域成長機會
  • 全球胜肽CXO市場的新趨勢
  • 戰略分析
    • 新產品開發
    • 全球胜肽CXO市場容量不斷擴大
    • 全球胜肽 CXO 市場的合併、收購和合資企業
    • 認證和許可

第7章主要企業公司簡介

  • Polypeptide
  • Bachem
  • LONZA
  • Bicycle
  • Pepscan
  • JPT Peptide
  • WuXi AppTec
  • Asymchem
  • Jiangsu Sinopep-Allsino Biopharmaceutical
  • Chinese Peptide Company

The future of the global peptide CXO market looks promising with opportunities in the pharmaceutical company and biotech company & research institution markets. The global peptide CXO market is expected to grow with a CAGR of 10.6% from 2025 to 2031. The major drivers for this market are the increasing demand for personalized medicine, the rising prevalence of chronic diseases, and the growing focus on targeted therapies.

  • Lucintel forecasts that, within the type category, CMO/CDMO is expected to witness higher growth over the forecast period.
  • Within the application category, biotech company & research institution is expected to witness higher growth.
  • In terms of region, APAC is expected to witness the highest growth over the forecast period.

Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below.

Emerging Trends in the Peptide CXO Market

The peptide CXO market is influenced by various prominent trends that address the changing needs of the biopharmaceutical industry as well as innovation in peptide synthesis and manufacturing technology.

  • Growing Need for Complex and Modified Peptides: The trend is growing demand for peptides with greater complexity, such as longer lengths, cyclic peptides, and chemical modifications such as PEGylation, lipidation, and glycosylation. These modifications provide improved peptide stability, bioavailability, and specificity to targets, leading to the requirement for CXOs with sophisticated synthesis and modification capacity.
  • Growing Adoption of Automation and High-Throughput Synthesis: To meet the increasing demand and reduce synthesis timelines, there is a growing adoption of automated and high-throughput peptide synthesis platforms. These technologies enable the parallel synthesis of multiple peptides, accelerating drug discovery and research processes while improving efficiency and reducing costs.
  • Green and Sustainable Peptide Synthesis: The world's growing interest in sustainability is compelling the world to move toward greener and more sustainable peptide synthesis processes. This involves using alternative solvents, minimizing waste generation, and employing more effective synthesis and purification strategies to lower the environmental burden of peptide production.
  • Incorporation of Sophisticated Analytical Methods: The need for pure peptides requires incorporation of sophisticated analytical methods for full characterization and quality assurance. This involves high-performance liquid chromatography (HPLC), mass spectrometry (MS), and nuclear magnetic resonance (NMR) spectroscopy to validate 1 peptide purity, identity, and structural integrity.
  • GMP-Grade Peptide Manufacturing Scale-Up: As the number of peptide therapeutics advances into clinical trials and commercializes, there is a vast scale-up of GMP (Good Manufacturing Practice)-grade peptide manufacturing capacity. CXOs are building infrastructure and capability to supply peptides that must adhere to demanding regulatory standards for use in human clinical trials and commercial drug products.

These new trends are cumulatively transforming the peptide CXO market by encouraging innovation in synthesis technologies, broadening the extent of peptides that can be produced, highlighting sustainability, improving quality control, and ramping up GMP production capacity to underpin the expanding space of peptide therapeutics.

Recent Developments in the Peptide CXO Market

Latest advances in the market for peptide CXO reflect continuing progress in synthesis, modification, and manufacturing technology, as well as growing concern with quality and regulatory compliance.

  • Advances in Novel Solid-Phase Synthesis Resins and Linkers: Advances in solid-phase synthesis involve the design of new resins and linkers that enhance peptide yield and purity and simplify the synthesis of difficult peptide sequences.
  • Developments in Continuous Flow Peptide Synthesis: Continuous flow synthesis is finding favor as an improved and scale-up process of peptide synthesis that is more efficient, with merits of reaction control, purity, and cost effectiveness.
  • Pushing the Capabilities of Enzymatic Peptide Synthesis: Enzymatic peptide synthesis is becoming the more environmentally friendly approach for individual peptide sequences due to high selectivity and being potentially less costly in terms of the use of aggressive chemicals.
  • Artificial Intelligence Integration in Peptide Design and Optimization: AI and machine learning-based algorithms are being increasingly utilized to predict peptide behavior, streamline synthesis protocols, and design new peptide sequences with target properties.
  • Greater Emphasis on Quality Systems and Regulatory Compliance: Peptide CXOs are putting more emphasis on compliance with highly stringent regulatory requirements, e.g., GMP, and on the establishment of effective quality management systems that guarantee the safety and efficacy of peptides synthesized for research and therapeutic use.

These essential advancements are revolutionizing the peptide CXO market by facilitating the synthesis of more complicated peptides more efficiently and with greater purity, encouraging sustainable process practices, utilizing computational technologies for peptide design, and adhering to stringent standards of quality for different purposes.

Strategic Growth Opportunities in the Peptide CXO Market

The peptide CXO market presents tremendous strategic growth opportunities across a broad spectrum of applications in the life sciences and pharmaceutical sectors.

  • Therapeutic Peptide Development: The growing number of peptide-based drugs under development for different diseases, such as cancer, diabetes, and cardiovascular disease, is a significant growth opportunity for CXOs offering bespoke synthesis and GMP manufacturing services.
  • Peptide-Based Diagnostics: Diagnostic applications of peptides, including imaging agents and biosensors, are increasing, providing opportunities for CXOs to design specialized peptides with particular labeling and targeting capabilities.
  • Cosmetic Peptides: Increasing demand for peptides in the cosmetics market for anti-aging and skin-improving products provides a niche market for CXOs who can produce high-purity cosmetic-grade peptides.
  • Agrochemical Peptides: Scientific studies of peptide-based agrochemicals, including crop defense agents and plant growth promoters, offer a promising future area for growth by CXOs who are experts in the synthesis of peptides on a large scale.
  • Peptides for Basic Research: Educational and research organizations need an extensive range of custom peptides to support basic investigations in biology, biochemistry, and materials science, thus providing a steady need for CXO services.

These strategic expansion opportunities in the therapeutic development, diagnostics, cosmetics, agrochemicals, and basic research areas demonstrate the widespread and increasing uses of synthetic peptides and fuel demand for expert CXO services.

Peptide CXO Market Driver and Challenges

The peptide CXO market is affected by a mix of drivers and challenges that influence its development and transformation in the wider life sciences sector.

The factors responsible for driving the peptide CXO market include:

1. Expanding Pipeline of Peptide Therapeutics: The rising pipeline of peptide drug candidates in clinical and preclinical development is one of the major drivers for peptide synthesis and manufacturing services demand.

2. Benefits of Peptide Therapeutics: Peptides have some benefits as therapeutics, such as high specificity, reduced toxicity versus small molecules, and targeting intracellular interactions, which is propelling their growing use.

3. New Technology Developments in Peptide Synthesis: Progressive development in solid-phase and liquid-phase peptide synthesis and introduction of novel technologies such as continuous flow and enzymatic synthesis is allowing for more elaborate and cost-effective peptides to be synthesized.

4. Expanding Funding in Life Science Research: Escalating private and public research investment in biotechnology and pharmaceutical research is fueling the use of custom peptides as tools in research and as leads in drugs.

5. Growth of the Biotechnology and Pharmaceutical Sectors in Emerging Economies: The high-speed development of the biopharmaceutical industry in countries such as China and India is opening up new opportunities for peptide CXOs to offer their services to local firms.

Challenges in the peptide CXO market are:

1. Technical Difficulty of Synthesizing Long and Altered Peptides: The technical difficulty of synthesizing longer peptide sequences and those with complex alterations can pose significant challenges, calling for expert technical skills and facilities.

2. High Peptide Synthesis Costs: The expense of peptide synthesis, particularly for peptides with modifications or those that must be synthesized under GMP-grade conditions, can be a prohibitive factor for certain research studies and smaller firms.

3. Regulatory Hurdles for Therapeutic Peptides: The regulatory environment for peptide therapeutics is complicated, with CXOs needing to comply with rigorous quality and manufacturing guidelines, which are expensive to put in place and maintain.

The CXO peptide market is witnessing robust growth fueled by the growing pipeline of peptide therapeutics, the intrinsic benefits of peptides as medicines, improved synthesis technologies, rising funding for research, and the rise of biopharma in emerging economies. Nevertheless, issues pertaining to synthesis complexity and cost, stringent regulation, competition from internal capabilities, and manufacturing scalability must be resolved in order for the market to maintain its success and grow further.

List of Peptide CXO Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies peptide CXO companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the peptide CXO companies profiled in this report include-

  • Polypeptide
  • Bachem
  • LONZA
  • Bicycle
  • Pepscan
  • JPT Peptide
  • WuXi AppTec
  • Asymchem
  • Jiangsu Sinopep-Allsino Biopharmaceutical
  • Chinese Peptide Company

Peptide CXO Market by Segment

The study includes a forecast for the global peptide CXO market by type, application, and region.

Peptide CXO Market by Type [Value from 2019 to 2031]:

  • CRO
  • CMO/CDMO

Peptide CXO Market by Application [Value from 2019 to 2031]:

  • Pharmaceutical Companies
  • Biotech Companies & Research Institutions
  • Others

Peptide CXO Market by Region [Value from 2019 to 2031]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Peptide CXO Market

The name "Peptide CXO" generally denotes custom peptide synthesis and production services provided to pharmaceutical and biotechnology firms, academic institutions, and research institutions. Such services address the expanding need for synthetic peptides in drug discovery, diagnostics, and basic research. Current trends in this market are defined by technological advances in peptide synthesis technologies, rising demand for complex and modified peptides, and the geographical spread of service providers. The demand for high-quality, cost-effective, and scalable peptide manufacturing is fueling innovation in this niche industry in many global regions.

  • United States: The US market for peptide CXO is mature, competitive, and highly focused on innovation and quality. Recent trends include the use of cutting-edge solid-phase peptide synthesis (SPPS) methods for the production of complex peptides and the incorporation of automation and high-throughput technologies. Increasing demand for peptide modifications like cyclization and PEGylation, as well as GMP-grade peptide production for clinical studies, is also being witnessed.
  • China: China's CXO market for peptides is growing at a fast pace, fueled by the growing biopharmaceutical industry and rising research activity. Local CXOs are improving their capacity to synthesize longer and more complex peptides, as well as providing more varied modifications. Advances have included upgrading quality control standards and rising emphasis on international collaborations and GMP compliance to support global customers.
  • Germany: Germany's CXO peptide market is dominated by a research-driven innovation and high-quality production focus. Recent trends have included the development of liquid-phase peptide synthesis (LPPS) for specialized use and new purification methods. There is also great importance placed on tailored peptide design and synthesis for research in academia and industry, as well as GMP-grade manufacture for use in the clinic.
  • India: The Indian peptide CXO market is becoming a budget-friendly option for peptide synthesis services. Latest news includes more and more local CXOs establishing capacity in solid-phase and liquid-phase synthesis. There is an increasing emphasis on following international standards of quality and offering peptide modifications and GMP-grade manufacturing capabilities to serve both domestic and foreign research and pharmaceutical requirements.
  • Japan: The Japanese peptide CXO market features a high value placed on top-quality and customized peptide synthesis. New trends encompass the development in synthesizing complex structure and modification peptides, mainly for therapeutic usage. Innovative techniques for peptide purification and analysis as well as GMP-compliant manufacturing for pharma development and clinical trials also feature.

Features of the Global Peptide CXO Market

  • Market Size Estimates: Peptide CXO market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
  • Segmentation Analysis: Peptide CXO market size by type, application, and region in terms of value ($B).
  • Regional Analysis: Peptide CXO market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the peptide CXO market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the peptide CXO market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the peptide CXO market by type (CRO and CMO/CDMO), application (pharmaceutical companies, biotech companies & research institutions, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Peptide CXO Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: PESTLE Analysis
  • 2.4: Patent Analysis
  • 2.5: Regulatory Environment
  • 2.6: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

  • 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
  • 3.2. Global Peptide CXO Market Trends (2019-2024) and Forecast (2025-2031)
  • 3.3: Global Peptide CXO Market by Type
    • 3.3.1: CRO: Trends and Forecast (2019 to 2031)
    • 3.3.2: CMO/CDMO: Trends and Forecast (2019 to 2031)
  • 3.4: Global Peptide CXO Market by Application
    • 3.4.1: Pharmaceutical Companies: Trends and Forecast (2019 to 2031)
    • 3.4.2: Biotech Companies & Research Institutions: Trends and Forecast (2019 to 2031)
    • 3.4.3: Others: Trends and Forecast (2019 to 2031)

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

  • 4.1: Global Peptide CXO Market by Region
  • 4.2: North American Peptide CXO Market
    • 4.2.1: North American Market by Type: CRO and CMO/CDMO
    • 4.2.2: North American Market by Application: Pharmaceutical Companies, Biotech Companies & Research Institutions, and Others
    • 4.2.3: The United States Peptide CXO Market
    • 4.2.4: Mexican Peptide CXO Market
    • 4.2.5: Canadian Peptide CXO Market
  • 4.3: European Peptide CXO Market
    • 4.3.1: European Market by Type: CRO and CMO/CDMO
    • 4.3.2: European Market by Application: Pharmaceutical Companies, Biotech Companies & Research Institutions, and Others
    • 4.3.3: German Peptide CXO Market
    • 4.3.4: French Peptide CXO Market
    • 4.3.5: Spanish Peptide CXO Market
    • 4.3.6: Italian Peptide CXO Market
    • 4.3.7: The United Kingdom Peptide CXO Market
  • 4.4: APAC Peptide CXO Market
    • 4.4.1: APAC Market by Type: CRO and CMO/CDMO
    • 4.4.2: APAC Market by Application: Pharmaceutical Companies, Biotech Companies & Research Institutions, and Others
    • 4.4.3: Japanese Peptide CXO Market
    • 4.4.4: Indian Peptide CXO Market
    • 4.4.5: Chinese Peptide CXO Market
    • 4.4.6: South Korean Peptide CXO Market
    • 4.4.7: Indonesian Peptide CXO Market
  • 4.5: ROW Peptide CXO Market
    • 4.5.1: ROW Market by Type: CRO and CMO/CDMO
    • 4.5.2: ROW Market by Application: Pharmaceutical Companies, Biotech Companies & Research Institutions, and Others
    • 4.5.3: Middle Eastern Peptide CXO Market
    • 4.5.4: South American Peptide CXO Market
    • 4.5.5: African Peptide CXO Market

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis
    • Competitive Rivalry
    • Bargaining Power of Buyers
    • Bargaining Power of Suppliers
    • Threat of Substitutes
    • Threat of New Entrants

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Peptide CXO Market by Type
    • 6.1.2: Growth Opportunities for the Global Peptide CXO Market by Application
    • 6.1.3: Growth Opportunities for the Global Peptide CXO Market by Region
  • 6.2: Emerging Trends in the Global Peptide CXO Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Peptide CXO Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Peptide CXO Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Polypeptide
    • Company Overview
    • Peptide CXO Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 7.2: Bachem
    • Company Overview
    • Peptide CXO Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 7.3: LONZA
    • Company Overview
    • Peptide CXO Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 7.4: Bicycle
    • Company Overview
    • Peptide CXO Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 7.5: Pepscan
    • Company Overview
    • Peptide CXO Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 7.6: JPT Peptide
    • Company Overview
    • Peptide CXO Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 7.7: WuXi AppTec
    • Company Overview
    • Peptide CXO Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 7.8: Asymchem
    • Company Overview
    • Peptide CXO Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 7.9: Jiangsu Sinopep-Allsino Biopharmaceutical
    • Company Overview
    • Peptide CXO Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 7.10: Chinese Peptide Company
    • Company Overview
    • Peptide CXO Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing

List of Figures

  • Figure 2.1: Classification of the Global Peptide CXO Market
  • Figure 2.2: Supply Chain of the Global Peptide CXO Market
  • Figure 3.1: Trends of the Global GDP Growth Rate
  • Figure 3.2: Trends of the Global Population Growth Rate
  • Figure 3.3: Trends of the Global Inflation Rate
  • Figure 3.4: Trends of the Global Unemployment Rate
  • Figure 3.5: Trends of the Regional GDP Growth Rate
  • Figure 3.6: Trends of the Regional Population Growth Rate
  • Figure 3.7: Trends of the Regional Inflation Rate
  • Figure 3.8: Trends of the Regional Unemployment Rate
  • Figure 3.9: Trends of Regional Per Capita Income
  • Figure 3.10: Forecast for the Global GDP Growth Rate
  • Figure 3.11: Forecast for the Global Population Growth Rate
  • Figure 3.12: Forecast for the Global Inflation Rate
  • Figure 3.13: Forecast for the Global Unemployment Rate
  • Figure 3.14: Forecast for the Regional GDP Growth Rate
  • Figure 3.15: Forecast for the Regional Population Growth Rate
  • Figure 3.16: Forecast for the Regional Inflation Rate
  • Figure 3.17: Forecast for the Regional Unemployment Rate
  • Figure 3.18: Forecast for Regional Per Capita Income
  • Figure 3.19: Global Peptide CXO Market by Type in 2019, 2024, and 2031 ($Billion)
  • Figure 3.20: Trends of the Global Peptide CXO Market ($B) by Type (2019-2024)
  • Figure 3.21: Forecast for the Global Peptide CXO Market ($B) by Type (2025-2031)
  • Figure 3.22: Trends and Forecast for CRO in the Global Peptide CXO Market (2019-2031)
  • Figure 3.23: Trends and Forecast for CMO/CDMO in the Global Peptide CXO Market (2019-2031)
  • Figure 3.24: Global Peptide CXO Market by Application in 2019, 2024, and 2031 ($Billion)
  • Figure 3.25: Trends of the Global Peptide CXO Market ($B) by Application (2019-2024)
  • Figure 3.26: Forecast for the Global Peptide CXO Market ($B) by Application (2025-2031)
  • Figure 3.27: Trends and Forecast for Pharmaceutical Companies in the Global Peptide CXO Market (2019-2031)
  • Figure 3.28: Trends and Forecast for Biotech Companies & Research Institutions in the Global Peptide CXO Market (2019-2031)
  • Figure 3.29: Trends and Forecast for Others in the Global Peptide CXO Market (2019-2031)
  • Figure 4.1: Trends of the Global Peptide CXO Market ($B) by Region (2019-2024)
  • Figure 4.2: Forecast for the Global Peptide CXO Market ($B) by Region (2025-2031)
  • Figure 4.3: Trends and Forecast for the North American Peptide CXO Market (2019-2031)
  • Figure 4.4: North American Peptide CXO Market by Type in 2019, 2024, and 2031 ($Billion)
  • Figure 4.5: Trends of the North American Peptide CXO Market ($B) by Type (2019-2024)
  • Figure 4.6: Forecast for the North American Peptide CXO Market ($B) by Type (2025-2031)
  • Figure 4.7: North American Peptide CXO Market by Application in 2019, 2024, and 2031 ($Billion)
  • Figure 4.8: Trends of the North American Peptide CXO Market ($B) by Application (2019-2024)
  • Figure 4.9: Forecast for the North American Peptide CXO Market ($B) by Application (2025-2031)
  • Figure 4.10: Trends and Forecast for the United States Peptide CXO Market (2019-2031)
  • Figure 4.11: Trends and Forecast for the Mexican Peptide CXO Market (2019-2031)
  • Figure 4.12: Trends and Forecast for the Canadian Peptide CXO Market (2019-2031)
  • Figure 4.13: Trends and Forecast for the European Peptide CXO Market (2019-2031)
  • Figure 4.14: European Peptide CXO Market by Type in 2019, 2024, and 2031 ($Billion)
  • Figure 4.15: Trends of the European Peptide CXO Market ($B) by Type (2019-2024)
  • Figure 4.16: Forecast for the European Peptide CXO Market ($B) by Type (2025-2031)
  • Figure 4.17: European Peptide CXO Market by Application in 2019, 2024, and 2031 ($Billion)
  • Figure 4.18: Trends of the European Peptide CXO Market ($B) by Application (2019-2024)
  • Figure 4.19: Forecast for the European Peptide CXO Market ($B) by Application (2025-2031)
  • Figure 4.20: Trends and Forecast for the German Peptide CXO Market (2019-2031)
  • Figure 4.21: Trends and Forecast for the French Peptide CXO Market (2019-2031)
  • Figure 4.22: Trends and Forecast for the Spanish Peptide CXO Market (2019-2031)
  • Figure 4.23: Trends and Forecast for the Italian Peptide CXO Market (2019-2031)
  • Figure 4.24: Trends and Forecast for the United Kingdom Peptide CXO Market (2019-2031)
  • Figure 4.25: Trends and Forecast for the APAC Peptide CXO Market (2019-2031)
  • Figure 4.26: APAC Peptide CXO Market by Type in 2019, 2024, and 2031 ($Billion)
  • Figure 4.27: Trends of the APAC Peptide CXO Market ($B) by Type (2019-2024)
  • Figure 4.28: Forecast for the APAC Peptide CXO Market ($B) by Type (2025-2031)
  • Figure 4.29: APAC Peptide CXO Market by Application in 2019, 2024, and 2031 ($Billion)
  • Figure 4.30: Trends of the APAC Peptide CXO Market ($B) by Application (2019-2024)
  • Figure 4.31: Forecast for the APAC Peptide CXO Market ($B) by Application (2025-2031)
  • Figure 4.32: Trends and Forecast for the Japanese Peptide CXO Market (2019-2031)
  • Figure 4.33: Trends and Forecast for the Indian Peptide CXO Market (2019-2031)
  • Figure 4.34: Trends and Forecast for the Chinese Peptide CXO Market (2019-2031)
  • Figure 4.35: Trends and Forecast for the South Korean Peptide CXO Market (2019-2031)
  • Figure 4.36: Trends and Forecast for the Indonesian Peptide CXO Market (2019-2031)
  • Figure 4.37: Trends and Forecast for the ROW Peptide CXO Market (2019-2031)
  • Figure 4.38: ROW Peptide CXO Market by Type in 2019, 2024, and 2031 ($Billion)
  • Figure 4.39: Trends of the ROW Peptide CXO Market ($B) by Type (2019-2024)
  • Figure 4.40: Forecast for the ROW Peptide CXO Market ($B) by Type (2025-2031)
  • Figure 4.41: ROW Peptide CXO Market by Application in 2019, 2024, and 2031 ($Billion)
  • Figure 4.42: Trends of the ROW Peptide CXO Market ($B) by Application (2019-2024)
  • Figure 4.43: Forecast for the ROW Peptide CXO Market ($B) by Application (2025-2031)
  • Figure 4.44: Trends and Forecast for the Middle Eastern Peptide CXO Market (2019-2031)
  • Figure 4.45: Trends and Forecast for the South American Peptide CXO Market (2019-2031)
  • Figure 4.46: Trends and Forecast for the African Peptide CXO Market (2019-2031)
  • Figure 5.1: Porter's Five Forces Analysis for the Global Peptide CXO Market
  • Figure 6.1: Growth Opportunities for the Global Peptide CXO Market by Type
  • Figure 6.2: Growth Opportunities for the Global Peptide CXO Market by Application
  • Figure 6.3: Growth Opportunities for the Global Peptide CXO Market by Region
  • Figure 6.4: Emerging Trends in the Global Peptide CXO Market

List of Table

  • Table 1.1: Growth Rate (%, 2019-2024) and CAGR (%, 2025-2031) of the Peptide CXO Market by Type and Application
  • Table 1.2: Attractiveness Analysis for the Peptide CXO Market by Region
  • Table 1.3: Global Peptide CXO Market Parameters and Attributes
  • Table 3.1: Trends of the Global Peptide CXO Market (2019-2024)
  • Table 3.2: Forecast for the Global Peptide CXO Market (2025-2031)
  • Table 3.3: Attractiveness Analysis for the Global Peptide CXO Market by Type
  • Table 3.4: Market Size and CAGR of Various Type in the Global Peptide CXO Market (2019-2024)
  • Table 3.5: Market Size and CAGR of Various Type in the Global Peptide CXO Market (2025-2031)
  • Table 3.6: Trends of CRO in the Global Peptide CXO Market (2019-2024)
  • Table 3.7: Forecast for the CRO in the Global Peptide CXO Market (2025-2031)
  • Table 3.8: Trends of CMO/CDMO in the Global Peptide CXO Market (2019-2024)
  • Table 3.9: Forecast for the CMO/CDMO in the Global Peptide CXO Market (2025-2031)
  • Table 3.10: Attractiveness Analysis for the Global Peptide CXO Market by Application
  • Table 3.11: Market Size and CAGR of Various Application in the Global Peptide CXO Market (2019-2024)
  • Table 3.12: Market Size and CAGR of Various Application in the Global Peptide CXO Market (2025-2031)
  • Table 3.13: Trends of Pharmaceutical Companies in the Global Peptide CXO Market (2019-2024)
  • Table 3.14: Forecast for the Pharmaceutical Companies in the Global Peptide CXO Market (2025-2031)
  • Table 3.15: Trends of Biotech Companies & Research Institutions in the Global Peptide CXO Market (2019-2024)
  • Table 3.16: Forecast for the Biotech Companies & Research Institutions in the Global Peptide CXO Market (2025-2031)
  • Table 3.17: Trends of Others in the Global Peptide CXO Market (2019-2024)
  • Table 3.18: Forecast for the Others in the Global Peptide CXO Market (2025-2031)
  • Table 4.1: Market Size and CAGR of Various Regions in the Global Peptide CXO Market (2019-2024)
  • Table 4.2: Market Size and CAGR of Various Regions in the Global Peptide CXO Market (2025-2031)
  • Table 4.3: Trends of the North American Peptide CXO Market (2019-2024)
  • Table 4.4: Forecast for the North American Peptide CXO Market (2025-2031)
  • Table 4.5: Market Size and CAGR of Various Type in the North American Peptide CXO Market (2019-2024)
  • Table 4.6: Market Size and CAGR of Various Type in the North American Peptide CXO Market (2025-2031)
  • Table 4.7: Market Size and CAGR of Various Application in the North American Peptide CXO Market (2019-2024)
  • Table 4.8: Market Size and CAGR of Various Application in the North American Peptide CXO Market (2025-2031)
  • Table 4.9: Trends of the European Peptide CXO Market (2019-2024)
  • Table 4.10: Forecast for the European Peptide CXO Market (2025-2031)
  • Table 4.11: Market Size and CAGR of Various Type in the European Peptide CXO Market (2019-2024)
  • Table 4.12: Market Size and CAGR of Various Type in the European Peptide CXO Market (2025-2031)
  • Table 4.13: Market Size and CAGR of Various Application in the European Peptide CXO Market (2019-2024)
  • Table 4.14: Market Size and CAGR of Various Application in the European Peptide CXO Market (2025-2031)
  • Table 4.15: Trends of the APAC Peptide CXO Market (2019-2024)
  • Table 4.16: Forecast for the APAC Peptide CXO Market (2025-2031)
  • Table 4.17: Market Size and CAGR of Various Type in the APAC Peptide CXO Market (2019-2024)
  • Table 4.18: Market Size and CAGR of Various Type in the APAC Peptide CXO Market (2025-2031)
  • Table 4.19: Market Size and CAGR of Various Application in the APAC Peptide CXO Market (2019-2024)
  • Table 4.20: Market Size and CAGR of Various Application in the APAC Peptide CXO Market (2025-2031)
  • Table 4.21: Trends of the ROW Peptide CXO Market (2019-2024)
  • Table 4.22: Forecast for the ROW Peptide CXO Market (2025-2031)
  • Table 4.23: Market Size and CAGR of Various Type in the ROW Peptide CXO Market (2019-2024)
  • Table 4.24: Market Size and CAGR of Various Type in the ROW Peptide CXO Market (2025-2031)
  • Table 4.25: Market Size and CAGR of Various Application in the ROW Peptide CXO Market (2019-2024)
  • Table 4.26: Market Size and CAGR of Various Application in the ROW Peptide CXO Market (2025-2031)
  • Table 5.1: Market Presence of Major Players in the Global Peptide CXO Market
  • Table 5.2: Operational Integration of the Global Peptide CXO Market
  • Table 6.1: New Product Launch by a Major Peptide CXO Producer (2019-2024)